Highlights•Dose selection for new combination therapy in tuberculosis has remained
empirical.•Novel tools are needed for effective translation of preclinical models to humans.•A …

The development of novel tuberculosis (TB) multi-drug regimens that are more efficacious
and of shorter duration requires a robust drug development pipeline. Advances in …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

The development of optimal treatment regimens in tuberculosis (TB) remains challenging
due to the need of combination therapy and possibility of pharmacodynamic (PD) …

Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …

Combination therapy has, to some extent, been successful in limiting the emergence of drug-
resistant tuberculosis. Drug combinations achieve this advantage by simultaneously acting …

Featured Application Model-informed drug discovery and development (MID3) is proposed
to be applied throughout the preclinical to clinical phases to provide an informative …

Aims Despite evidence of the efficacy of anti‐tubercular drug regimens in clinical practice,
the rationale underpinning the selection of doses and companion drugs for combination …

To tackle the global TB epidemic effectively, novel treatment strategies are critically needed
to shorten the duration of TB therapy and treat drug-resistant TB. Drug development for TB …

Introduction: Understanding drug exposure at disease target sites is pivotal to profiling new
drug candidates in terms of tolerability and efficacy. Such quantification is particularly …